Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer
https://doi.org/10.17650/1726-9776-2016-12-1-106-114
Abstract
Objective: to carry out a pharmacoeconomic analysis of using tyrosine kinase inhibitors for the targeted therapy of disseminated renal cell carcinoma.
Materials and methods. The data on the efficacy and safety of therapy with tyrosine kinase inhibitors were obtained from the analysis of the results of clinical trials selected during an information search. The pharmacoeconomic analysis used the following methods: cost analysis, budget impact analysis, cost miniminization analysis, and sensitivity analysis.
Results. The performed investigation demonstrated that the use of pazopanib in patients with disseminated renal cell carcinoma was expedient from an economic standpoint and less effective than that of sunitinib. The cost of an annual cycle of pazopanib treatment in Russia was not found to be greater than the payment readiness threshold. Analysis of the purchase amount of tyrosine kinase inhibitors for the treatment of renal cell carcinoma in 2014 demonstrated that the use of pazopanib could reduce government spending by 290.2 million (21.6%) rubles per year. This saving of budgetary funds provides a way of treating additional 375 people per 1,000 patients when using pazopanib. The administration of pazopanib with its existing purchase amount for the treatment of disseminated renal cell carcinoma will be able to reduce government spending by 1.4 milliard rubles during 5 years, which corresponds to the current annual costs of tyrosine kinase inhibitors.
Conclusion. The use of pazopanib makes it possible to reduce government spending on 1st line targeted therapy of advanced RCC in comparison with sunitinib with comparable efficacy of both agents.
About the Authors
S. K. Zyryanov
Department of Clinical Pharmacology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
1, Ostrovityanov St., Moscow 117997
Russian Federation
1, Ostrovityanov St., Moscow 117997
M. Yu. Frolov
Volgograd State Medical University, Ministry of Health of Russia; Volgograd Medical Research Center
Russian Federation
1, Pavshikh Bortsov Square, Volgograd 400131,
Russian Federation
1, Pavshikh Bortsov Square, Volgograd 400131,
I. N. Dyakov
I.I. Mechnikov Research Institute of Vaccines and Sera
Russian Federation
5a, Malyi Kazennyi Lane, Moscow 105064
Russian Federation
5a, Malyi Kazennyi Lane, Moscow 105064
References
1. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. [Malignant tumors in Russia in 2014: morbidity and fatality. Ed. by А.D. Kaprin, V.V. Starinsky, G.V. Petrova. М., 2016. (In Russ.)].
2. Vrdoljak E., Torday L., Szczylik C. et al. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe, Expert Opinion on Pharmacotherapy. 2016;17:(1)93–104, DOI: 10.1517/14656566.2016.1107043.
3. Матвеев В.Б., Волкова М.И. Последовательная таргетная терапия при диссеминированном раке почки. Онкоурология 2013;(1):28–33. [Маtveev V.B., Volkovа М.I. Consequent target therapy at the disseminated kidney cancer. Onkourologiya = Оncourology 2013;(1):28–33. (In Russ.)].
4. Kovacs G., Аkhtar M., Beckwith B.J. et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131–3.
5. Аляев Ю.Г., Крапивин А.А. Локализованный и местно-распространенный рак почки: нефрэктомия или резекция. Онкоурология 2005;(1) :10–15. [Аlyaev Y.G., Krapivin А.А. Localized and locally spread kidney cancer: nephrectomy or resection. Onkourologiya = Оncourology 2005;(1):10–15. (In Russ.)].
6. Анализ государственных аукционов по закупке лекарственных препаратов сунитиниб и пазопаниб для государственных и муниципальных нужд в 2014 г. База данных IMS Health. [Аnalysis of state auctions for the purchase of such pharmaceuticals and sunitinib and pazopanib for state and municipal needs in 2014. IMS Health data base. (In Russ.)].
7. О проблеме отказа в лекарственных препаратах онкологическим пациентам в России. Отчет за 2014 год, МОД «Движение против рака», Москва, 2015. [Оn the problems of the refuse of pharmaceuticals to oncologic patients in Russia. Report of 2014. МRD “AntiCancer Movement”. М., 2015. (In Russ.)].
8. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115–24.
9. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8.
10. Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renalcell carcinoma. N Engl J Med 2013;369(8):722–31.
11. Государственный реестр лекарственных средств. http://grls.rosminzdrav.ru/GRLS.aspх. [State sector of pharmaceuticals. http://grls.rosminzdrav.ru/GRLS.aspx. (In Russ.)].
12. Государственный реестр предельных отпускных цен. http://grls.rosminzdrav.ru/pricelims.aspx. [State registry of marginal retail prices. http://grls.rosminzdrav.ru/pricelims.aspx. (In Russ.)].
13. Широкорад В.И., Махсон А.Н., Борисов В.И. и др. Первые результаты таргетной терапии при раке почки в Москве. Онкоурология 2013;(3):24–9. [Shirokorad V. I., Маhson А. N., Borisov V. N. etc. First results of target therapy at kidney cancer in Moscow. Onkourologiya = Оncourology 2013;(3):24–9. (In Russ.)].
14. Федеральная служба государственной статистики http://www.gks.ru/. [Federal State Statistics Service http://www.gks.ru/.(In Russ.)].
15. Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Дисконтирование при проведении фармакоэкономических исследований. Фармакоэкономика 2009;2(4):10–3. [Yagudina R.I., Kulikov А. Y., Serpik V.G. Discounting at pharmacoeconomic studies. Farmakoekonomika = Pharmacoeconomica 2009;2(4):10–3. (In Russ.)].
16. Leibovich B.C., Blute M.L. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663–71.
17. Онкоурология: национальное руководство. Под ред. В.И. Чиссова, Б.Я. Алексеева, И.Г. Русакова. М.: ГЭОТАР-Медиа, 2012. 688 с. [Оncourology: national guideline. Ed.by V.I. Chissov, B.Y. Аlexeev, I.G. Rusakov. М.: GEOTAR-Меdiа, 2012. 688 p. (In Russ.)].
Review
For citations:
Zyryanov S.K., Frolov M.Yu., Dyakov I.N. Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer. Cancer Urology. 2016;12(1):106-114. https://doi.org/10.17650/1726-9776-2016-12-1-106-114
Views:
76289
Email this article 